WeVote
Log In

Bill

Bill

SB 294

Enacting the Kansas medical cannabis act to authorize the cultivation, processing, distribution, sale and use of medical cannabis and medical cannabis products.

2025-2026 Regular Session

Kansas bill would legalize medical cannabis cultivation, processing, and sales through state-regulated licensing system for qualified patients with physician recommendations.

Died in Committee
#cannabis #crimes #punishmentandcriminalprocedure #discrimination #funds #healthandenvironment #departmentof #healthandhealthcare #namedacts #workerscompensation
0
WeVote Research Nonpartisan
Bill Summary · SB 294

Legislative bill overview

SB 294 would establish a comprehensive medical cannabis regulatory framework in Kansas, legalizing the cultivation, processing, distribution, sale, and use of cannabis for qualified patients with physician recommendations. The bill would create a state licensing system to oversee producers, processors, retailers, and testing facilities while defining eligible medical conditions and patient protections.

Why is this important

Kansas currently prohibits all cannabis use, making it one of the more restrictive states. This bill would potentially provide treatment access for patients with chronic pain, epilepsy, PTSD, and other conditions while generating tax revenue and creating jobs in cultivation, retail, and ancillary industries. The change would also align Kansas with 38+ other states that have legalized medical cannabis.

Potential points of contention

  • Federal-state conflict: Cannabis remains a Schedule I controlled substance federally, creating legal uncertainty for businesses and patients despite state legalization
  • Implementation costs and timeline: Establishing regulatory agencies, licensing systems, and testing infrastructure requires significant state resources and regulatory expertise
  • Workplace and driving safety: Defining impairment standards, workplace policies, and DUI enforcement remains scientifically complex and legally contentious
  • Access equity: Determining which conditions qualify, licensing fees, and geographic distribution could create disparities in patient access
  • Public health concerns: Opponents raise questions about youth access prevention, potency standards, and long-term health effects

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.